8-K: Centessa Pharmaceuticals Announces Positive Data and Financial Results for Q4 and Full-Year 2024

Centessa Pharmaceuticals reports progress in its orexin receptor 2 (OX2R) agonist program and financial results for the fourth quarter and full year ended December 31, 2024, with key data readouts expected in 2025.

Summary

• Centessa Pharmaceuticals announced its financial results for Q4 and the full year 2024.
• The company's cash, cash equivalents, and short-term investments totaled $482.2 million as of December 31, 2024, which is expected to fund operations into mid-2027.
• R&D expenses were $60.9 million for Q4 2024, compared to $29.7 million for Q4 2023, and $150.2 million for the full year 2024, compared to $124.4 million for the full year 2023.
• The R&D expenses for the quarter and full year 2024 included a one-time charge of $31.5 million related to the discontinuation of the global clinical development program for SerpinPC.
• General and administrative expenses were $13.7 million for Q4 2024, compared to $12.3 million for Q4 2023, and $50.8 million for the full year 2024, compared to $53.7 million for the full year 2023.
• Net loss was $111.3 million for Q4 2024, compared to $36.8 million for Q4 2023, and $235.8 million for the full year 2024, compared to $151.1 million for the full year 2023.
• The net loss for the quarter and full year 2024 reflects non-recurring items including a $34.1 million loss on debt extinguishment and a charge of $31.5 million related to the discontinuation of the global clinical development program for SerpinPC.
• Data from the Phase 1 study of ORX750 will be presented in a poster session at the American Academy of Neurology (AAN) Annual Meeting on April 5, 2025.
• The company expects to share Phase 2a data for ORX750 across all three indications (NT1, NT2, and IH) in 2025.
• The company is focused on obtaining IND clearance for ORX142 and initiating clinical development with the goal of sharing clinical data in acutely sleep-deprived healthy volunteers in 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, it also highlighted positive data from its ORX750 program and has a strong cash position. The progress in its pipeline and potential for best-in-class OX2R agonists contribute to the positive aspects.

Positives

• The company has a strong cash position of $482.2 million, expected to fund operations into mid-2027.
• Phase 1 data for ORX750 showed promising results in increasing wakefulness and a favorable safety profile.
• The Phase 2a CRYSTAL-1 study for ORX750 is ongoing and expected to provide data across multiple indications in 2025.
• The company is advancing multiple OX2R agonists (ORX142 and ORX489) through IND-enabling studies.
• Centessa is pioneering a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders.

Negatives

• The company reported a significant net loss of $235.8 million for the full year 2024.
• R&D expenses increased significantly to $150.2 million for the full year 2024.
• The company incurred a one-time charge of $31.5 million related to the discontinuation of the SerpinPC program.
• The company incurred a $34.1 million loss on debt extinguishment.

Risks

• The success of the company's pipeline depends on the outcome of clinical trials, which are subject to inherent risks and uncertainties.
• The company's ability to obtain regulatory clearance for its product candidates is not guaranteed.
• The company faces competition from other pharmaceutical companies developing treatments for similar indications.
• Economic risks to the United States and United Kingdom banking systems could impact the company's financial stability.
• Geo-political risks such as the Russia-Ukraine war or the Middle East conflicts could impact the company's operations.

Future Outlook

Centessa expects 2025 to be a data-rich year, with key data readouts expected from the ORX750 Phase 2a CRYSTAL-1 study and the potential initiation of clinical development for ORX142.

Management Comments

• Centessa is proud to be at the forefront of developing OX2R agonists, a groundbreaking new drug class with the potential to transform the standard of care for patients across multiple therapeutic areas, said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
• Our teams drug optimization techniques have enabled a growing pipeline of novel, potential best-in-class OX2R agonists aimed at restoring normative wakefulness for individuals living with excessive daytime sleepiness (EDS) in neurological, neurodegenerative and neuropsychiatric disorders, and potentially addressing other key symptoms such as impaired attention, cognitive deficits and fatigue.
• Our most advanced OX2R agonist, ORX750, is progressing in the Phase 2a CRYSTAL-1 study for the treatment of NT1, NT2 and IH, and is on track with data expected across all three indications this year.
• Based on the strength of these data, we believe ORX750 has the potential to be best-in-class and to enable the full range of doses required to meet the needs of patients living with NT1, NT2 and IH.
• In addition to the transformational potential of ORX750 for individuals living with sleep-wake disorders, we see tremendous opportunity with our follow-up OX2R agonists that are being advanced for the treatment of EDS, impaired attention, cognitive deficits and fatigue in neurological, neurodegenerative and neuropsychiatric disorders.

Industry Context

Centessa's focus on OX2R agonists places it in a competitive landscape with other companies developing treatments for sleep disorders and neurological conditions. The company aims to differentiate itself through its drug optimization techniques and potential best-in-class profile of its lead candidate, ORX750.

Comparison to Industry Standards

• The orexin receptor 2 (OX2R) agonist program is a novel approach to treating sleep disorders, and there are limited direct comparables.
• Other companies developing treatments for narcolepsy and idiopathic hypersomnia include Jazz Pharmaceuticals (Xyrem, Xywav) and Avadel Pharmaceuticals (Lumryz), which primarily target GABA receptors.
• Centessa's approach of targeting the orexin pathway with OX2R agonists represents a different mechanism of action and could potentially offer advantages in terms of efficacy and safety compared to existing treatments.
• The company's goal of achieving MSL >30 minutes in the Maintenance of Wakefulness Test (MWT) is a clinically meaningful endpoint and aligns with industry standards for assessing wakefulness in patients with sleep disorders.
• The favorable safety and tolerability profile observed in the Phase 1 study of ORX750 is also an important factor in differentiating it from other treatments, as some existing medications for sleep disorders are associated with significant side effects.

Stakeholder Impact

• Shareholders: The financial results and pipeline progress will impact shareholder value.
• Patients: The development of new treatments for sleep disorders could improve the quality of life for patients.
• Employees: The company's progress and financial stability will impact employee morale and job security.
• Investors: The company's cash position and pipeline progress will attract potential investors.

Next Steps

• Share Phase 2a data for ORX750 across all three indications (NT1, NT2, and IH) in 2025.
• Present data from the Phase 1 study of ORX750 at the AAN Annual Meeting on April 5, 2025.
• Obtain IND clearance for ORX142 and initiate clinical development with the goal of sharing clinical data in acutely sleep-deprived healthy volunteers in 2025.
• Continue advancing ORX489 in IND-enabling studies.

Key Dates

Keywords

Centessa Pharmaceuticals, OX2R agonist, ORX750, ORX142, ORX489, Narcolepsy, Idiopathic Hypersomnia, Clinical Trials, Financial Results, Pharmaceuticals